AstraZeneca Secures Dual Rare Disease and Bladder Cancer Approvals Across US, Europe
Source: Benzinga ·

Regulators in the U.S. and European Union handed AstraZeneca Plc (NYSE:AZN) major regulatory wins across rare neuromuscular disease and oncology. The agencies cleared Klygefa for generalized myasthenia gravis and approved the Imfinzi combination regimen for muscle-invasive bladde
Read the full story at Benzinga
Shared from the GodsView world desk: live wires next to a globe of flights, ships, fires, and quakes.